Low-Level Laser Therapy Improves Vision in Patients with Age-Related Macular Degeneration

Boris T. Ivandic, M.D., 1 and Tomislav Ivandic, M.D. 2

Abstract

Objective: The objective of this study of a case series was to examine the effects of low-level laser therapy (LLLT) in patients with age-related macular degeneration (AMD).

Background Data: AMD affects a large proportion of the elderly population; current therapeutic options for AMD are limited, however.

Patients and Methods: In total, 203 patients (90 men and 113 women; mean age 63.4 ± 5.3 y) with beginning (“dry”) or advanced (“wet”) forms of AMD (n = 348 eyes) were included in the study. One hundred ninety-three patients (mean age 64.6 ± 4.3 y; n = 328 eyes) with cataracts (n = 182 eyes) or without cataracts (n = 146 eyes) were treated using LLLT four times (twice per week). A semiconductor laser diode (780 nm, 7.5 mW, 292 Hz, continuous emission) was used for transconjunctival irradiation of the macula for 40 sec (0.3 J/cm2) resulting in a total dose of 1.2 J/cm2. Ten patients (n = 20 eyes) with AMD received mock treatment and served as controls. Visual acuity was measured at each visit. Data were analyzed retrospectively using a t-test.

Results: LLLT significantly improved visual acuity (p < 0.00001 versus baseline) in 162/182 (95%) of eyes with cataracts and 142/146 (97%) of eyes without cataracts. The prevalence of metamorphopsia, scotoma, and dyschromatopsia was reduced. In patients with wet AMD, edema and bleeding improved. The improved vision was maintained for 3–36 mo after treatment. Visual acuity in the control group remained unchanged. No adverse effects were observed in those undergoing therapy.

Conclusion: In patients with AMD, LLLT significantly improved visual acuity without adverse side effects and may thus help to prevent loss of vision.

Introduction

AGE-RELATED MACULAR DEGENERATION (AMD) is the predominant cause of irreversible loss of vision in the elderly. AMD affects 30–50% of individuals 60 years or older.1,2 AMD-related disability and poor quality of life are likely to increase the socio-economic burden in the elderly living in industrialized countries.3

AMD results from defects in the choriocapillaris, Bruch’s membrane, and the retinal pigment epithelium (RPE) underneath the macula. The epitheliopathy diminishes lysosomal activity and phagocytosis of the outer photoreceptors and disrupts the transportation of cell debris through the RPE to the choriocapillaris.4 The resulting accumulation of cell debris in Bruch’s membrane leads to thickening and hydrophobic charging of the membrane.5 This suffocates the photoreceptors and promotes fibrovascular proliferation and the formation of subretinal exudates. Ultimately, the decay of the retina results in loss of vision.6

Current therapeutic approaches aim to stabilize the remaining vision because photoreceptor function appears to be irreversibly lost. Treatment options, such as photodynamic therapy, laser photocoagulation, transpupillary thermotherapy, ionizing radiation, and surgery have been applied with limited success in cases of exudative, advanced AMD.7,8 These treatments may also produce collateral damage of the foveal neurosensory retina and impair visual function further. At present, antioxidant and mineral dietary supplements as well as anti-angiogenetic drugs are being discussed as alternative treatment options.9–12

LLLT represents a novel therapeutic method that, other than surgical laser applications, does not damage tissues. In this study of a case series we investigated the effects of LLLT in patients with AMD of all forms and stages, and varying degrees of vision impairment.

1University of Heidelberg, Otto-Meyerhof Centre, Heidelberg, and 2Medical Centre, Munich, Germany.
Patients and Methods

Study design

This study of a case series was conducted in accordance with the Helsinki declaration. Informed consent was obtained from all patients before entry into the study. Data were collected at a single non-institutional center in Germany during a 7-year period and were evaluated retrospectively.

Patients

Patients with AMD of all stages (dry to wet exudative forms with or without cataracts) were included if their visual acuity was $\geq 20/20$. Patients were excluded if they had concomitant diseases that would impair vision except for new cataracts, or if they had received any prior treatment that could have affected vision; patients with visual acuity $>20/20$ were also excluded.

Laser

For LLLT, a semiconductor laser diode with continuous emission at 780 nm (7.5 mW, 292 Hz) fitted with collimating optics (spot diameter = 3 mm) in a handheld casing was used. The laser diode was driven by an apparatus that allowed low-frequency switching of the laser beam and provided automatic power control (Bimed, Munich, Germany).

In an initial experiment, the extinction of laser light ($\lambda = 780$ nm) was examined in a freshly enucleated pig eye (22 × 24 mm) to determine the lowest penetrating laser power required for the laser energy to reach the RPE and retina. Power output was measured using a LC-U-2E power meter (Laser Components GmbH, Olching, Germany).

Treatment

As illustrated in Fig. 1, laser radiation was applied transconjunctivally to the macula for 40 sec (0.3 J/cm²). During LLLT the eye was in adduction; if necessary, the lids were fixed manually.

Four treatments were administered (two treatments per week) resulting in a total dose of 1.2 J/cm². Ten patients with AMD (n = 20 eyes) were randomly selected to receive mock treatment (control group); the laser beam was directed above the nose without contacting the eye. An audible signal heard every 10 sec was interpreted by the patients as treatment. During the treatment period, no other therapy was applied.

Measurements

Eyes were examined before inclusion, prior to each treatment session, and at the end of the study. Visual acuity was assessed by projection of American Optical optotypes (Snellen) at a distance of 20 feet after optimal correction of refraction with blinding. In order to avoid patient memorization of the letters, only unknown optotypes were presented each time. Color vision was examined by use of a desaturated color test (Farnsworth D-15 series). The Amsler test was used to screen central scotomas.

To assess treatment safety, the investigator examined the patients’ eyes before and after each treatment session and asked patients about their general well-being by asking non-leading questions.

Data analysis

Data on visual acuity were analyzed by calculating the changes in visual acuity (end of study versus baseline); data were transformed logarithmically to allow presentation of results as logarithmic minimal angle resolution (log MAR). For statistical analysis, a t-test for paired observations was used.

### Table 1

<table>
<thead>
<tr>
<th>Input laser power, $I_0$ (mW)</th>
<th>Tissue(s)</th>
<th>Output laser power, $I$ (mW)</th>
<th>Extinction $(E = \log I_0/I)$</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.5</td>
<td>Cornea</td>
<td>10.5</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Lens</td>
<td>11.0</td>
<td>-0.20</td>
</tr>
<tr>
<td></td>
<td>Sclera</td>
<td>4.2</td>
<td>0.397</td>
</tr>
<tr>
<td></td>
<td>Choroidea</td>
<td>2.9</td>
<td>0.558</td>
</tr>
<tr>
<td></td>
<td>RPE</td>
<td>1.5</td>
<td>0.845</td>
</tr>
<tr>
<td></td>
<td>Retina</td>
<td>8.8</td>
<td>0.076</td>
</tr>
<tr>
<td></td>
<td>Conjunctiva-sclera-choroidea-RPE-retina</td>
<td>0.2</td>
<td>1.720</td>
</tr>
</tbody>
</table>

RPE, retinal pigmented epithelium.
Results

Determination of laser power

Initial experimentation on a freshly enucleated pig eye aimed to determine the optimum power level of laser energy to be used in this study. By using a low sub-thermal dose of radiation (10.5 mW), only a small proportion of the energy reached the retina (Table 1). The largest proportion was absorbed by the sclera, choroidea, and RPE. The data indicated that a power output of 10.3 mW was required for the laser light to pass through all layers of the eye.

Demographic characteristics

In total, 203 patients (90 men and 113 women) with AMD of various stages (n = 348 eyes) and a mean age of 63.4 ± 5.3 y were included in the study. All patients received treatment as planned; none of the patients withdrew from the study.

One hundred ninety-three patients (mean age 64.6 ± 4.3 y) were treated using LLLT; of 328 treated eyes, 146 (45%) eyes were without cataracts, and 182 (55%) eyes were with cataracts. Eye examination revealed that 230 eyes had drusen or were depigmented; geographic atrophy was noted in 12 eyes. Progressive, exudative AMD was diagnosed in 86 eyes with no other disorders. Examples of early-stage and advanced AMD are shown in Figs. 2 and 3, respectively.

Changes in visual acuity

There was a statistically significant increase in visual acuity (p < 0.00001, end of study versus baseline) for both patients with and those without cataracts. The improvement in visual acuity was maintained for 3–36 mo. By contrast, visual acuity remained unchanged in all patients in the control group.

In patients without cataracts (Table 2), visual acuity improved in 142/146 eyes (97.3%; p < 0.00001): by one row of

<table>
<thead>
<tr>
<th>Table 2. Visual Acuity Before and After LLLT in Patients with AMD Without Cataracts (n = 146 Eyes)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before therapy</td>
</tr>
<tr>
<td>Visual acuity</td>
</tr>
<tr>
<td>After therapy</td>
</tr>
<tr>
<td>Number of eyes are in bold type.</td>
</tr>
<tr>
<td>log MAR, logarithmic minimal angle resolution.</td>
</tr>
</tbody>
</table>
optotypes in 29/146 (19.8%), by two rows in 54/146 (37.0%),
by three rows in 28/146 (19.2%), by four or five rows in
12/146 (8.2%), by six rows in 6/146 (4.1%) and by seven rows
in 1/146 (0.7%). Visual acuity remained unchanged in 4/146
eyes (2.7%).

In patients with cataracts (Table 3), visual acuity improved
in 172/182 eyes (94.5%; p < 0.00001) eyes: by one row of op-
totypes in 45/182 (24.7%), by two rows in 75/182 (41.2%),
by three rows in 25/182 (13.7%), by four rows in 16/182
(8.8%), by five rows in 7/182 (3.8%), by six rows in 3/182
(1.6%), and by seven rows in 1/182 (0.5%). Visual acuity re-
mained unchanged in 10/182 eyes (5.5%).

Changes in concomitant eye disorders

In patients treated with LLLT the improvement in visual
acuity was in most cases accompanied by a decrease in meta-
morphopsias, scotomas, and acquired dyschromatopsia (Fig.
4). In patients with wet AMD, edema and bleeding were re-
duced.

Safety and tolerability

The treatment was well tolerated. No adverse local or sys-
temic side effects were observed.

Discussion

LLLT given over 2 wk led to an improvement in visual
acuity in most patients with AMD (>90%). An increase of
three to seven rows of optotypes was observed in 52/182
(28.6%) of eyes with cataracts, and in 59/146 (40.4%) of eyes
without cataracts. Unlike other therapeutic approaches,
LLLT improved visual acuity in patients with AMD of every

<table>
<thead>
<tr>
<th>Visual acuity</th>
<th>20/400</th>
<th>20/200</th>
<th>20/100</th>
<th>20/80</th>
<th>20/70</th>
<th>20/60</th>
<th>20/50</th>
<th>20/40</th>
<th>20/30</th>
<th>20/25</th>
<th>20/20</th>
<th>20/16</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20/400</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20/200</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20/100</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20/80</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20/70</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20/60</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20/50</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20/40</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20/30</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20/25</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20/20</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20/16</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Number of eyes are in bold type.
log MAR, logarithmic minimal angle resolution.

FIG. 4. Normalization of impaired color vision in a 49-year-old patient. Farnsworth color test results (Series D-15) before (left) and after (right) four treatments with LLLT. Visual acuity increased from 20/30 to 20/16.
stage. The improvement in visual function was maintained for up to 36 mo.

The results of this retrospective analysis of a case series are encouraging, especially in light of the fact that if untreated, AMD inevitably leads to irreversible loss of vision. Thus LLLT may, when initiated during the early stages of AMD, help prevent loss of vision. LLLT may also be combined with other therapeutic approaches. Although not investigated in this study, it is likely that synergistic effects may be seen (e.g., improved outcome or shorter treatment duration).

In addition to the improvement in visual acuity, other positive effects of LLLT were noted. Eye examinations revealed that LLLT diminished pigment accumulations and cystic drusen. Metamorphopsia, acquired impairments of color vision, and relative scotomas improved as well. Moreover, in patients with wet AMD, edema and bleeding were reduced.

Treatment with laser energy at a wavelength of 780 nm was not perceived as unpleasant and was well accepted by the patients. No adverse effects were observed.

In general, the photochemical effects of light are mediated through the interaction of photons and various cellular acceptor molecules. Thus, photon energy is transformed into biochemical energy, which stimulates metabolic reactions. LLLT may increase cellular metabolism in choroida, RPE, and in photoreceptors, where the energy is absorbed by pigments. Regular metabolic processes may be enhanced and repair processes may be triggered or accelerated. Recently, an increase in the expression of heat shock proteins was found in the retinal and choroidal layers after sub-thermal transpupillary application of laser energy. Heat shock proteins (or chaperones) are known to stimulate cellular metabolism and may help prevent premature cell death. In in vitro experiments, application of laser light was shown to increase cellular metabolic activity, the generation of adenosine triphosphate, and phagocytosis. Enhanced lysosomal activity and phagocytosis of cell debris and pigments may help to revitalize the retina. The detailed cellular and molecular mechanisms underlying the biomedical effects of laser energy in the treatment of patients with AMD have yet to be further elucidated.

Conclusion

In conclusion, this study of a case series shows that LLLT may be a novel therapeutic option for both early and advanced forms of AMD. This simple and highly effective treatment improves visual acuity and may help to prevent loss of vision without adverse side effects.

References


Address reprint requests to:
Dr. Boris T. Ivandic, M.D.
University of Heidelberg
Otto-Meyerhof Centre
Im Neuenheimer Feld 350
69120 Heidelberg, Germany
E-mail: boris.ivandic@med.uni-heidelberg.de